{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:25:43Z","timestamp":1793157943147,"version":"4.5.0"},"reference-count":106,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["813343"],"award-info":[{"award-number":["813343"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["H2020-MSCA-ITN-2019"],"award-info":[{"award-number":["H2020-MSCA-ITN-2019"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.coi.2023.102282","type":"journal-article","created":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T01:07:08Z","timestamp":1674868028000},"page":"102282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Cell entry and innate sensing shape adaptive immune responses to adenovirus-based vaccines"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4067-0394","authenticated-orcid":false,"given":"Sonia","family":"Marquez-Martinez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneesh","family":"Vijayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Zahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2023.102282_bib1","unstructured":"EMA: Zabdeno (Ad26.ZEBOV-GP, recombinant) an overview of Zabdeno and why it is authorised in the EU. 2020. EMA\/298997\/2020."},{"key":"10.1016\/j.coi.2023.102282_bib2","unstructured":"EMA: Jcovden1 (COVID-19 vaccine (Ad26.COV2-S [recombinant])) an overview of Jcovden and why it is authorised in the EU. 2022. EMA\/203645\/2022."},{"key":"10.1016\/j.coi.2023.102282_bib3","unstructured":"EMA: Vaxzevria1 (COVID-19 Vaccine (ChAdOx1-S [recombinant])). an overview of Vaxzevria and why it is authorised in the EU. 2022. EMA\/110683\/2022."},{"key":"10.1016\/j.coi.2023.102282_bib4","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/978-3-030-58971-4_16","article-title":"Structural organization and protein-protein interactions in human adenovirus capsid","volume":"96","author":"Reddy","year":"2021","journal-title":"Subcell Biochem"},{"key":"10.1016\/j.coi.2023.102282_bib5","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3181\/00379727-84-20714","article-title":"Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture","volume":"84","author":"Rowe","year":"1953","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.coi.2023.102282_bib6","doi-asserted-by":"crossref","first-page":"5523","DOI":"10.1128\/JVI.02667-05","article-title":"Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity","volume":"80","author":"Krause","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2023.102282_bib7","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1128\/jvi.70.3.1836-1844.1996","article-title":"Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues","volume":"70","author":"Crawford-Miksza","year":"1996","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2023.102282_bib8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.molcel.2004.11.041","article-title":"The structure of the human adenovirus 2 penton","volume":"17","author":"Zubieta","year":"2005","journal-title":"Mol Cell"},{"key":"10.1016\/j.coi.2023.102282_bib9","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jmb.2010.11.043","article-title":"Model of the trimeric fiber and its interactions with the pentameric penton base of human adenovirus by cryo-electron microscopy","volume":"406","author":"Liu","year":"2011","journal-title":"J Mol Biol"},{"key":"10.1016\/j.coi.2023.102282_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-54939-9","article-title":"Unravelling receptor and RGD motif dependence of retargeted adenoviral vectors using advanced tumor model systems","volume":"9","author":"Chernyavska","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.coi.2023.102282_bib11","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.virol.2008.10.016","article-title":"Insights into adenovirus host cell interactions from structural studies","volume":"384","author":"Nemerow","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.coi.2023.102282_bib12","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0092-8674(80)90362-1","article-title":"DNA replication and the early to late transition in adenovirus infection","volume":"22","author":"Thomas","year":"1980","journal-title":"Cell"},{"key":"10.1016\/j.coi.2023.102282_bib13","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1128\/JVI.72.5.4049-4056.1998","article-title":"Control of adenovirus early gene expression during the late phase of infection","volume":"72","author":"Fessler","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2023.102282_bib14","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1128\/jvi.70.4.2431-2439.1996","article-title":"The role of human adenovirus early region 3 proteins (gp19K, 10.4K, 14.5K, and 14.7K) in a murine pneumonia model","volume":"70","author":"Sparer","year":"1996","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2023.102282_bib15","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1128\/MCB.19.5.3885","article-title":"Distinct regulation of p53 and p73 activity by adenovirus E1A, E1B, and E4orf6 proteins","volume":"19","author":"Steegenga","year":"1999","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.coi.2023.102282_bib16","doi-asserted-by":"crossref","first-page":"d1369","DOI":"10.2741\/ben","article-title":"Adenovirus and cell cycle control","volume":"7","author":"Ben-Israel","year":"2002","journal-title":"Front Biosci"},{"key":"10.1016\/j.coi.2023.102282_bib17","doi-asserted-by":"crossref","first-page":"5703","DOI":"10.1128\/JVI.00491-11","article-title":"Members of the Adenovirus Research C: toward an integrated human adenovirus designation system that utilizes molecular and serological data and serves both clinical and fundamental virology","volume":"85","author":"Aoki","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2023.102282_bib18","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1128\/JVI.00354-11","article-title":"Members of the adenovirus research C: using the whole-genome sequence to characterize and name human adenoviruses","volume":"85","author":"Seto","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2023.102282_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-021-00356-x","article-title":"Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic","volume":"6","author":"Mendonca","year":"2021","journal-title":"NPJ Vaccin"},{"key":"10.1016\/j.coi.2023.102282_bib20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/mt.2015.194","article-title":"Development of novel adenoviral vectors to overcome challenges observed with HAdV-5-based constructs","volume":"24","author":"Alonso-Padilla","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2023.102282_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21144821","article-title":"Non-human primate-derived adenoviruses for future use as oncolytic agents?","volume":"21","author":"Bots","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coi.2023.102282_bib22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/sj.gt.3300825","article-title":"Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement","volume":"6","author":"Ji","year":"1999","journal-title":"Gene Ther"},{"key":"10.1016\/j.coi.2023.102282_bib23","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1006\/mthe.2001.0264","article-title":"Generation and characterization of E1\/E2a\/E3\/E4-deficient adenoviral vectors encoding human factor VIII","volume":"3","author":"Andrews","year":"2001","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2023.102282_bib24","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1566523213666131125095046","article-title":"Adenovirus vectors for gene therapy, vaccination and cancer gene therapy","volume":"13","author":"Wold","year":"2013","journal-title":"Curr Gene Ther"},{"key":"10.1016\/j.coi.2023.102282_bib25","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-1-4939-9065-8_9","article-title":"Current use of adenovirus vectors and their production methods","volume":"1937","author":"Sayedahmed","year":"2019","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.coi.2023.102282_bib26","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0140-6736(18)31364-3","article-title":"Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1\/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)","volume":"392","author":"Barouch","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2023.102282_bib27","volume":"5","author":"Green","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.coi.2023.102282_bib28","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/mt.2013.284","article-title":"Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens","volume":"22","author":"Antrobus","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2023.102282_bib29","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ebiom.2018.02.011","article-title":"Heterologous two-dose vaccination with simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to Influenza virus A in healthy adults","volume":"29","author":"Coughlan","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.coi.2023.102282_bib30","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1002\/1873-3468.13696","article-title":"Innate immunity to adenovirus: lessons from mice","volume":"593","author":"Atasheva","year":"2019","journal-title":"FEBS Lett"},{"key":"10.1016\/j.coi.2023.102282_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00909","article-title":"Factors which contribute to the immunogenicity of non-replicating adenoviral vectored vaccines","volume":"11","author":"Coughlan","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2023.102282_bib32","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1002\/jgm.553","article-title":"Adenovirus endocytosis","volume":"6","author":"Meier","year":"2004","journal-title":"J Gene Med"},{"key":"10.1016\/j.coi.2023.102282_bib33","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.addr.2007.06.007","article-title":"Intracellular trafficking of adenovirus: many means to many ends","volume":"59","author":"Leopold","year":"2007","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.coi.2023.102282_bib34","doi-asserted-by":"crossref","first-page":"14429","DOI":"10.1128\/JVI.79.22.14429-14436.2005","article-title":"CD46 is a cellular receptor for all species B adenoviruses except types 3 and 7","volume":"79","author":"Marttila","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2023.102282_bib35","doi-asserted-by":"crossref","first-page":"7909","DOI":"10.1128\/JVI.72.10.7909-7915.1998","article-title":"The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F","volume":"72","author":"Roelvink","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2023.102282_bib36","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nm.2270","article-title":"Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14","volume":"17","author":"Wang","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2023.102282_bib37","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1128\/JVI.01392-12","article-title":"Circulating antibodies and macrophages as modulators of adenovirus pharmacology","volume":"87","author":"Khare","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2023.102282_bib38","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1128\/JVI.78.9.4454-4462.2004","article-title":"The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3","volume":"78","author":"Sirena","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2023.102282_bib39","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/nm952","article-title":"CD46 is a cellular receptor for group B adenoviruses","volume":"9","author":"Gaggar","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2023.102282_bib40","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1128\/JVI.79.12.7503-7513.2005","article-title":"Localization of regions in CD46 that interact with adenovirus","volume":"79","author":"Gaggar","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2023.102282_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006914","article-title":"Lung macrophage scavenger receptor SR-A6 (MARCO) is an adenovirus type-specific virus entry receptor","volume":"14","author":"Stichling","year":"2018","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coi.2023.102282_bib42","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.virusres.2006.07.009","article-title":"Members of adenovirus species B utilize CD80 and CD86 as cellular attachment receptors","volume":"122","author":"Short","year":"2006","journal-title":"Virus Res"},{"key":"10.1016\/j.coi.2023.102282_bib43","unstructured":"GSK, TH HBV VV-001 clinical study. Annex IIIA according to Directive 2001\/18\/EC Information Required in Notifications Concerning Releases of Genetically Modified Organisms Other than Higher Plants 11-12, 2018, 15-16."},{"key":"10.1016\/j.coi.2023.102282_bib44","unstructured":"GSK, RSV-PED-011 clinical study. Annex IIIA according to Directive 2001\/18\/EC Information Required in Notifications Concerning Releases of Genetically Modified Organisms Other than Higher Plants 2018, 14:18-19."},{"key":"10.1016\/j.coi.2023.102282_bib45","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1345","article-title":"Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections","volume":"10","author":"Elkashif","year":"2021","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.coi.2023.102282_bib46","series-title":"19-Xenogenic Adenoviral Vectors A2-Curiel, David T Adenoviral Vectors for Gene Therapy","author":"Mittal","year":"2016"},{"key":"10.1016\/j.coi.2023.102282_bib47","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2008.01.016","article-title":"Adenovirus serotype 5 hexon mediates liver gene transfer","volume":"132","author":"Waddington","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.coi.2023.102282_bib48","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/mt.2012.287","article-title":"SR-A and SREC-I are Kupffer and endothelial cell receptors for helper-dependent adenoviral vectors","volume":"21","author":"Piccolo","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2023.102282_bib49","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1189\/jlb.0612311","article-title":"CRIg mediates early Kupffer cell responses to adenovirus","volume":"93","author":"He","year":"2013","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.coi.2023.102282_bib50","article-title":"Key role of the scavenger receptor MARCO in mediating adenovirus infection and subsequent innate responses of macrophages","volume":"8","author":"Maler","year":"2017","journal-title":"mBio"},{"key":"10.1016\/j.coi.2023.102282_bib51","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1161\/01.ATV.21.2.238","article-title":"Vascular cell adhesion molecule-1 augments adenovirus-mediated gene transfer","volume":"21","author":"Chu","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.coi.2023.102282_bib52","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1093\/emboj\/16.9.2294","article-title":"Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells","volume":"16","author":"Hong","year":"1997","journal-title":"EMBO J"},{"key":"10.1016\/j.coi.2023.102282_bib53","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1089\/104303403765255165","article-title":"Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice","volume":"14","author":"Smith","year":"2003","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.coi.2023.102282_bib54","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.1128\/JVI.77.8.4858-4866.2003","article-title":"Binding of adenovirus capsid to dipalmitoyl phosphatidylcholine provides a novel pathway for virus entry","volume":"77","author":"Balakireva","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2023.102282_bib55","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc6659","article-title":"Systemic cancer therapy with engineered adenovirus that evades innate immunity","volume":"12","author":"Atasheva","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2023.102282_bib56","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1099\/vir.0.008342-0","article-title":"Adenovirus serotype 5 infects human dendritic cells via a coxsackievirus-adenovirus receptor-independent receptor pathway mediated by lactoferrin and DC-SIGN","volume":"90","author":"Adams","year":"2009","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coi.2023.102282_bib57","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/sj.gt.3302675","article-title":"Chimpanzee-origin adenovirus vectors as vaccine carriers","volume":"13","author":"Tatsis","year":"2006","journal-title":"Gene Ther"},{"key":"10.1016\/j.coi.2023.102282_bib58","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax3567","article-title":"Human adenovirus type 26 uses sialic acid-bearing glycans as a primary cell entry receptor","volume":"5","author":"Baker","year":"2019","journal-title":"Sci Adv"},{"key":"10.1016\/j.coi.2023.102282_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/v13081483","article-title":"In vitro and in vivo evaluation of human adenovirus type 49 as a vector for therapeutic applications","volume":"13","author":"Bates","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.coi.2023.102282_bib60","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01474-18","article-title":"Alphavbeta3 integrin is required for efficient infection of epithelial cells with human adenovirus type 26","volume":"93","author":"Nestic","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2023.102282_bib61","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abl8213","article-title":"ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome","volume":"7","author":"Baker","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.coi.2023.102282_bib62","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1099\/0022-1317-83-1-151","article-title":"Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor","volume":"83","author":"Cohen","year":"2002","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coi.2023.102282_bib63","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1016\/j.vaccine.2016.07.028","article-title":"Strain-dependent and distinctive T-cell responses to HIV antigens following immunisation of mice with differing chimpanzee adenovirus vaccine vectors","volume":"34","author":"Herath","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2023.102282_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004657","article-title":"Human adenovirus 52 uses sialic acid-containing glycoproteins and the coxsackie and adenovirus receptor for binding to target cells","volume":"11","author":"Lenman","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coi.2023.102282_bib65","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1128\/JVI.05760-11","article-title":"Identification of adenovirus serotype 5 hexon regions that interact with scavenger receptors","volume":"86","author":"Khare","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2023.102282_bib66","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/mt.2011.71","article-title":"Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer","volume":"19","author":"Khare","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2023.102282_sbref62","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.7150\/jca.46463","article-title":"A tropism-transformed oncolytic adenovirus with dual capsid modifications for enhanced glioblastoma therapy","volume":"11","author":"Wang","year":"2020","journal-title":"J Cancer"},{"key":"10.1016\/j.coi.2023.102282_bib68","doi-asserted-by":"crossref","first-page":"10274","DOI":"10.1128\/JVI.74.22.10274-10286.2000","article-title":"Dependence of adenovirus infectivity on length of the fiber shaft domain","volume":"74","author":"Shayakhmetov","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2023.102282_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018205","article-title":"Cell entry and trafficking of human adenovirus bound to blood factor X is determined by the fiber serotype and not hexon:heparan sulfate interaction","volume":"6","author":"Corjon","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2023.102282_sbref65","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/s41434-021-00308-z","article-title":"Biodistribution and immunity of adenovirus 5\/35 and modified vaccinia Ankara vector vaccines against human immunodeficiency virus 1 clade C","volume":"29","author":"Shimada","year":"2022","journal-title":"Gene Ther"},{"key":"10.1016\/j.coi.2023.102282_sbref66","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00826-21","article-title":"Ex vivo and in vivo CD46 receptor utilization by species D human adenovirus serotype 26 (HAdV26)","volume":"96","author":"Hemsath","year":"2022","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2023.102282_bib72","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s11259-009-9307-3","article-title":"Detection of expression of influenza virus receptors in tissues of BALB\/c mice by histochemistry","volume":"33","author":"Ning","year":"2009","journal-title":"Vet Res Commun"},{"key":"10.1016\/j.coi.2023.102282_bib73","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1099\/vir.0.81293-0","article-title":"Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors","volume":"87","author":"Verhaagh","year":"2006","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coi.2023.102282_bib74","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/emboj.2008.38","article-title":"Subversion of CtBP1-controlled macropinocytosis by human adenovirus serotype 3","volume":"27","author":"Amstutz","year":"2008","journal-title":"EMBO J"},{"key":"10.1016\/j.coi.2023.102282_bib75","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1002\/j.1460-2075.1993.tb05919.x","article-title":"Difference imaging of adenovirus: bridging the resolution gap between X-ray crystallography and electron microscopy","volume":"12","author":"Stewart","year":"1993","journal-title":"EMBO J"},{"key":"10.1016\/j.coi.2023.102282_bib76","doi-asserted-by":"crossref","first-page":"12367","DOI":"10.1128\/JVI.01833-13","article-title":"A direct and versatile assay measuring membrane penetration of adenovirus in single cells","volume":"87","author":"Suomalainen","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2023.102282_bib77","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.3390\/v2102290","article-title":"Tropism-modification strategies for targeted gene delivery using adenoviral vectors","volume":"2","author":"Coughlan","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.coi.2023.102282_bib78","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/0092-8674(93)90382-Z","article-title":"Stepwise dismantling of adenovirus 2 during entry into cells","volume":"75","author":"Greber","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.coi.2023.102282_bib79","doi-asserted-by":"crossref","first-page":"10354","DOI":"10.1128\/JVI.00936-14","article-title":"Late endosomal trafficking of alternative serotype adenovirus vaccine vectors augments antiviral innate immunity","volume":"88","author":"Teigler","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2023.102282_bib80","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008180","article-title":"Alpha-defensin 5 differentially modulates adenovirus vaccine vectors from different serotypes in vivo","volume":"15","author":"Tartaglia","year":"2019","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coi.2023.102282_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/v14050888","article-title":"Cytokine responses to adenovirus and adenovirus vectors","volume":"14","author":"Atasheva","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.coi.2023.102282_bib82","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/ni.2548","article-title":"Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21","volume":"14","author":"McEwan","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coi.2023.102282_bib83","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1128\/JVI.02702-13","article-title":"Adenovirus detection by the cGAS\/STING\/TBK1 DNA sensing cascade","volume":"88","author":"Lam","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2023.102282_bib84","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.virusres.2015.06.018","article-title":"RNA: an essential pro-viral non-coding RNA","volume":"212","author":"Vachon","year":"2016","journal-title":"Virus Res"},{"key":"10.1016\/j.coi.2023.102282_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008017","article-title":"Adenovirus early region 3 RIDalpha protein limits NFkappaB signaling through stress-activated EGF receptors","volume":"15","author":"Zeng","year":"2019","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coi.2023.102282_bib86","unstructured":"CDSCO: COVID-19 vaccines approved in the country. 2022, 1-2."},{"key":"10.1016\/j.coi.2023.102282_bib87","unstructured":"WHO: Interim recommendations for use of the Cansino Ad5-nCoV-S vaccine (Convidecia \u00ae) against COVID-19. 2022."},{"key":"10.1016\/j.coi.2023.102282_sbref81","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.579872","article-title":"Innate immune responses to chimpanzee adenovirus vector 155 vaccination in mice and monkeys","volume":"11","author":"Collignon","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2023.102282_bib89","doi-asserted-by":"crossref","first-page":"9590","DOI":"10.1128\/JVI.00740-12","article-title":"Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys","volume":"86","author":"Teigler","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2023.102282_bib90","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.ymthe.2021.03.020","article-title":"Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan","volume":"29","author":"Younis","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2023.102282_bib91","doi-asserted-by":"crossref","first-page":"E3503","DOI":"10.1073\/pnas.1208972109","article-title":"Merck Ad5\/HIV induces broad innate immune activation that predicts CD8(+) T-cell responses but is attenuated by preexisting Ad5 immunity","volume":"109","author":"Zak","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coi.2023.102282_bib92","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/sj.mt.6300024","article-title":"Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector","volume":"15","author":"Hensley","year":"2007","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2023.102282_bib93","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1172\/JCI78280","article-title":"Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling","volume":"125","author":"Quinn","year":"2015","journal-title":"J Clin Investig"},{"key":"10.1016\/j.coi.2023.102282_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2022.102210","article-title":"Viral vector vaccines","volume":"77","author":"McCann","year":"2022","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coi.2023.102282_bib95","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.4049\/jimmunol.1103717","article-title":"Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity","volume":"188","author":"Johnson","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2023.102282_bib96","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1128\/JVI.01597-10","article-title":"Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors","volume":"85","author":"Rhee","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2023.102282_sbref90","article-title":"Innate immune responses of vaccinees determine early neutralizing antibody production after ChAdOx1nCoV-19 vaccination","volume":"13","author":"Shen","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2023.102282_bib98","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.4049\/jimmunol.0901022","article-title":"Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response","volume":"184","author":"Panda","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2023.102282_sbref92","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1126\/science.aax8819","article-title":"MAIT cell activation augments adenovirus vector vaccine immunogenicity","volume":"371","author":"Provine","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.coi.2023.102282_bib100","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/j.celrep.2019.01.104","article-title":"Influenza vaccination induces NK-cell-mediated type-II IFN response that regulates humoral immunity in an IL-6-dependent manner","volume":"26","author":"Farsakoglu","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.coi.2023.102282_bib101","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.immuni.2007.03.017","article-title":"Regulation of activated CD4+ T cells by NK cells via the Qa-1-NKG2A inhibitory pathway","volume":"26","author":"Lu","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.coi.2023.102282_bib102","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.molimm.2012.02.119","article-title":"Adenovirus type 35, but not type 5, stimulates NK cell activation via plasmacytoid dendritic cells and TLR9 signaling","volume":"51","author":"Pahl","year":"2012","journal-title":"Mol Immunol"},{"key":"10.1016\/j.coi.2023.102282_bib103","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-019-0132-6","article-title":"The how's and what's of vaccine reactogenicity","volume":"4","author":"Herve","year":"2019","journal-title":"NPJ Vaccin"},{"key":"10.1016\/j.coi.2023.102282_sbref97","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975363","article-title":"COVID-19 vaccine type-dependent differences in immunogenicity and inflammatory response: BNT162b2 and ChAdOx1 nCoV-19","volume":"13","author":"Heo","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2023.102282_bib105","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1080\/22221751.2022.2059404","article-title":"Transcriptomic analysis of the innate immune signatures of a SARS-CoV-2 protein subunit vaccine ZF2001 and an mRNA vaccine RRV","volume":"11","author":"Wang","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.coi.2023.102282_bib106","unstructured":"EMA Guideline on non-clinical testing for inadvertent germline transmission of gene transfer vectors 2006 EMEA\/273974\/2005 4."}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791523000018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791523000018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:12:40Z","timestamp":1778778760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791523000018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":106,"alternative-id":["S0952791523000018"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2023.102282","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cell entry and innate sensing shape adaptive immune responses to adenovirus-based vaccines","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2023.102282","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102282"}}